Emerging role of immunotherapy in urothelial carcinoma—Immunobiology/biomarkers

Urologic Oncology: Seminars and Original Investigations

Volumn 34, Issue 12, 2016, Pages 556-565

  Sweis, Randy F ^a   Galsky, Matthew D ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; Bladder cancer; Immune checkpoint therapy; Immunology; Urothelial cancer

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOMODULATING AGENT; PROGRAMMED DEATH 1 LIGAND 1; TUMOR ANTIGEN; TUMOR MARKER; ATEZOLIZUMAB; CD274 PROTEIN, HUMAN; IMMUNOLOGICAL ADJUVANT; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR; TUMOR PROTEIN;

CANCER IMMUNOTHERAPY; GENE EXPRESSION; HUMAN; IMMUNOBIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TRANSITIONAL CELL CARCINOMA; TUMOR IMMUNOLOGY; TUMOR MICROENVIRONMENT; ANTAGONISTS AND INHIBITORS; ANTIGEN PRESENTING CELL; BLADDER TUMOR; CHEMISTRY; CLINICAL TRIAL (TOPIC); CYTOTOXIC T LYMPHOCYTE; EXPERIMENTAL THERAPY; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MOLECULARLY TARGETED THERAPY; MUTATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, MONOCLONAL; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; B7-H1 ANTIGEN; CARCINOMA, TRANSITIONAL CELL; CLINICAL TRIALS AS TOPIC; COSTIMULATORY AND INHIBITORY T-CELL RECEPTORS; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM PROTEINS; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, CYTOTOXIC; THERAPIES, INVESTIGATIONAL; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; URINARY BLADDER NEOPLASMS;

EID: 84997530136     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2016.10.006     Document Type: Review

References (89)

1. [1] Morales, A., Eidinger, D., Bruce, A.W., Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116 (1976), 180–183 [PubMed PMID: 820877].
2. [2] Steinberg, G., Bahnson, R., Brosman, S., Middleton, R., Wajsman, Z., Wehle, M., Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 163 (2000), 761–767 [PubMed PMID: 10687972].
3. [3] Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136 (2015), E359–E386, 10.1002/ijc.29210 [PubMed PMID: 25220842].
4. [4] Redelman-Sidi, G., Glickman, M.S., Bochner, B.H., The mechanism of action of BCG therapy for bladder cancer—a current perspective. Nat Rev Urol 11 (2014), 153–162, 10.1038/nrurol.2014.15 [PubMed PMID: 24492433].
5. [5] Powles, T., Eder, J.P., Fine, G.D., Braiteh, F.S., Loriot, Y., Cruz, C., et al. MPDL32.8.0. A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515 (2014), 558–562, 10.1038/nature13904 [PubMed PMID: 25428503].
6. [6] Bracarda, S., Altavilla, A., Hamzaj, A., Sisani, M., Marrocolo, F., Del Buono, S., et al. Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies. Semin Oncol 42 (2015), 495–505, 10.1053/j.seminoncol.2015.02.004 [PubMed PMID: 25965369].
7. [7] Carosella, E.D., Ploussard, G., LeMaoult, J., Desgrandchamps, F., A systematic review of immunotherapy in urologic cancer: evolving roles for targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol 68 (2015), 267–279, 10.1016/j.eururo.2015.02.032 [PubMed PMID: 2582472].
8. [8] Kim, J.W., Tomita, Y., Trepel, J., Apolo, A.B., Emerging immunotherapies for bladder cancer. Curr Opin Oncol 27 (2015), 191–200, 10.1097/CCO.0000000000000177 [PubMed PMID: 25811346].
9. [9] Schumacher, T.N., Schreiber, R.D., Neoantigens in cancer immunotherapy. Science 348 (2015), 69–74, 10.1126/science.aaa4971 [PubMed PMID: 25838375].
10. [10] Fuertes, M.B., Woo, S.R., Burnett, B., Fu, Y.X., Gajewski, T.F., Type I interferon response and innate immune sensing of cancer. Trends Immunol 34 (2013), 67–73, 10.1016/j.it.2012.10.004 [PubMed PMID: 23122052; PMCID: PMC3565059].
11. [11] Diamond, M.S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G.P., Archambault, J.M., et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 208 (2011), 1989–2003, 10.1084/jem.20101158 [PubMed PMID: 21930769; PMCID: PMC3182061].
12. [12] Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Aparicio, S.A., Behjati, S., Biankin, A.V., et al. Signatures of mutational processes in human cancer. Nature 500 (2013), 415–421, 10.1038/nature12477 [PubMed PMID: 23945592; PMCID: PMC3776390].
13. [13] Cazier, J.B., Rao, S.R., McLean, C.M., Walker, A.K., Walker, A.L., Wright, B.J., et al. Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden. Nat Commun, 5, 2014, 3756, 10.1038/ncomms4756 [PubMed PMID: 24777035; PMCID: PMC4010643].
14. [14] Network CGAR, Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507 (2014), 315–322, 10.1038/nature12965 [PubMed PMID: 24476821; PMCID: PMC3962515].
15. [15] Sharpe, A.H., Freeman, G.J., The B7-CD28 superfamily. Nat Rev Immunol 2 (2002), 116–126, 10.1038/nri727 [PubMed PMID: 11910893].
16. [16] Lenschow, D.J., Walunas, T.L., Bluestone, J.A., CD28/B7 system of T cell costimulation. Annu Rev Immunol 14 (1996), 233–258, 10.1146/annurev.immunol.14.1.233 [PubMed PMID: 8717514].
17. [17] Bour-Jordan, H., Esensten, J.H., Martinez-Llordella, M., Penaranda, C., Stumpf, M., Bluestone, J.A., Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/B7 family. Immunol Rev 241 (2011), 180–205, 10.1111/j.1600-065X.2011.01011.x [PubMed PMID: 21488898; PMCID: PMC3077803].
18. [18] Watts, T.H., TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 23 (2005), 23–68, 10.1146/annurev.immunol.23.021704.115839 [PubMed PMID: 15771565].
19. [19] Driessens, G., Kline, J., Gajewski, T.F., Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev 229 (2009), 126–244, 10.1111/j.1600-065X.2009.00771.x [PubMed PMID: 19426219; PMCID: PMC3278040].
20. [20] Taraban, V.Y., Rowley, T.F., O'Brien, L., Chan, H.T., Haswell, L.E., Green, M.H., et al. Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses. Eur J Immunol 32 (2002), 3617–3627, 10.1002/1521-4141(200212)32:12<3617::AID-IMMU3617>3.0.CO;2-M [PubMed PMID: 12516549].
21. [21] Williams, J.B., Horton, B., Zheng, Y., Gajewski, T.F., LAG-3 and 4-1BB identify dysfunctional antigen-specific T cells in the tumor microenvironment and combinatorial LAG-3/4-1BB targeting gives synergistic tumor control. J Immunother Cancer, 3(Suppl 2), 2015, P328-P, 10.1186/2051-1426-3-S2-P328 [PubMed PMID: PMC4649320].
22. [22] Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12 (2012), 252–264, 10.1038/nrc3239 [PubMed PMID: 22437870].
23. [23] Yang, M., Yu, Q., Liu, J., Fu, W., Cao, Y., Yu, L., et al. T-cell immunoglobulin mucin-3 expression in bladder urothelial carcinoma: clinicopathologic correlations and association with survival. J Surg Oncol 112 (2015), 430–435, 10.1002/jso.24012 [PubMed PMID: 26265374].
24. [24] Mukherji, D., Jabbour, M.N., Saroufim, M., Temraz, S., Nasr, R., Charafeddine, M., et al. Programmed death-ligand 1 expression in muscle-invasive bladder cancer cystectomy specimens and lymph node metastasis: a reliable treatment selection biomarker?. Clin Genitourin Cancer, 2015, 10.1016/j.clgc.2015.12.002 [PubMed PMID: 26775720].
25. [25] Bellmunt, J., Mullane, S.A., Werner, L., Fay, A.P., Callea, M., Leow, J.J., et al. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol 26 (2015), 812–817, 10.1093/annonc/mdv009 [PubMed PMID: 25600565].
26. [26] Boorjian, S.A., Sheinin, Y., Crispen, P.L., Farmer, S.A., Lohse, C.M., Kuntz, S.M., et al. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res 14 (2008), 4800–4808, 10.1158/1078-0432.CCR-08-0731 [PubMed PMID: 18676751].
27. [27] Carthon, B.C., Wolchok, J.D., Yuan, J., Kamat, A., Ng Tang, D.S., Sun, J., et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 16 (2010), 2861–2871, 10.1158/1078-0432.CCR-10-0569 [PubMed PMID: 20460488; PMCID: PMC2919850].
28. [28] Sweis, R.F., Spranger, S., Bao, R., Paner, G.P., Stadler, W.M., Steinberg, G.D., et al. Molecular drivers of the non-T Cell-inflamed tumor microenvironment in urothelial bladder cancer. Cancer Immunol Res, 2016, 10.1158/2326-6066.CIR-15-0274 [PubMed PMID: 27197067].
29. [29] Sharma, P., Shen, Y., Wen, S., Yamada, S., Jungbluth, A.A., Gnjatic, S., et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A 104 (2007), 3967–3972, 10.1073/pnas.0611618104 [PubMed PMID: 17360461; PMCID: PMC1820692].
30. [30] Melero, I., Gaudernack, G., Gerritsen, W., Huber, C., Parmiani, G., Scholl, S., et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol 11 (2014), 509–524, 10.1038/nrclinonc.2014.111 [PubMed PMID: 25001465].
31. [31] Steinberg, G., Shore, N., Karsh, L., Bailen, J., Woods, M., Schreiber, T., et al. Phase I study of patients with non-muscle invasive bladder cancer (NMIBC) treated with vesigenurtacel-L (HS-410) after Bacillus Calmette-Guérin (BCG). J Immunother Cancer, 3(Suppl 2), 2015, P447, 10.1186/2051-1426-3-S2-P447 [PubMed PMID: PMC4652496].
32. [32] Noguchi, M., Matsumoto, K., Uemura, H., Arai, G., Eto, M., Naito, S., et al. An open-label, randomized phase II trial of personalized peptide vaccination in patients with bladder cancer that progressed after platinum-based chemotherapy. Clin Cancer Res 22 (2016), 54–60, 10.1158/1078-0432.CCR-15-1265 [PubMed PMID: 26581246].
33. [33] Perica, K., Varela, J.C., Oelke, M., Schneck, J., Adoptive T cell immunotherapy for cancer. Rambam Maimonides Med J, 6, 2015, e0004, 10.5041/RMMJ.10179 [PubMed PMID: 25717386; PMCID: PMC4327320].
34. [34] Sherif, A., Hasan, M.N., Radecka, E., Rodriguez, A.L., Shabo, S., Karlsson, M., et al. Pilot study of adoptive immunotherapy with sentinel node-derived T cells in muscle-invasive urinary bladder cancer. Scand J Urol, 2015, 1–10, 10.3109/21681805.2015.1059880 [PubMed PMID: 26144252.
35. [35] Maude, S.L., Teachey, D.T., Porter, D.L., Grupp, S.A., CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood 125 (2015), 4017–4023, 10.1182/blood-2014-12-580068 [PubMed PMID: 25999455; PMCID: PMC4481592].
36. [36] Hong, H., Stastny, M., Brown, C., Chang, W.C., Ostberg, J.R., Forman, S.J., et al. Diverse solid tumors expressing a restricted epitope of L1-CAM can be targeted by chimeric antigen receptor redirected T lymphocytes. J Immunother 37 (2014), 93–104, 10.1097/CJI.0000000000000018 [PubMed PMID: 24509172].
37. [37] Katari, U.L., Keirnan, J.M., Worth, A.C., Hodges, S.E., Leen, A.M., Fisher, W.E., et al. Engineered T cells for pancreatic cancer treatment. HPB (Oxford), 13, 2011, 643–650, 10.1111/j.1477–2574.2011.00344.x [PubMed PMID: 21843265; PMCID: PMC3183449].
38. [38] Kaufman, H.L., Kohlhapp, F.J., Zloza, A., Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 14 (2015), 642–662, 10.1038/nrd4663 [PubMed PMID: 26323545].
39. [39] Burke, J.M., Lamm, D.L., Meng, M.V., Nemunaitis, J.J., Stephenson, J.J., Arseneau, J.C., et al. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol 188 (2012), 2391–2397, 10.1016/j.juro.2012.07.097 [PubMed PMID: 23088985].
40. [40] Grossman, H.B., Liebert, M., Antelo, M., Dinney, C.P., Hu, S.X., Palmer, J.L., et al. p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 4 (1998), 829–834 [PubMed PMID: 9563875].
41. [41] Santos, M., Martínez-Fernández, M., Dueñas, M., García-Escudero, R., Alfaya, B., Villacampa, F., et al. In vivo disruption of an Rb-E2F-Ezh2 signaling loop causes bladder cancer. Cancer Res 74 (2014), 6565–6577, 10.1158/0008-5472.CAN-14-1218 [PubMed PMID: 25252918; PMCID: PMC4233185].
42. [42] Leach, D.R., Krummel, M.F., Allison, J.P., Enhancement of antitumor immunity by CTLA-4 blockade. Science 271 (1996), 1734–1736 [PubMed PMID: 8596936].
43. [43] Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 (2010), 711–723, 10.1056/NEJMoa1003466 [PubMed PMID: 20525992; PMCID: PMC3549297].
44. [44] Schadendorf, D., Hodi, F.S., Robert, C., Weber, J.S., Margolin, K., Hamid, O., et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33 (2015), 1889–1894, 10.1200/JCO.2014.56.2736 [PubMed PMID: 25667295].
45. [45] Rosenberg, S.A., Raising the bar: the curative potential of human cancer immunotherapy. Sci Transl Med, 4, 2012, 127ps8, 10.1126/scitranslmed.3003634 [PubMed PMID: 22461638].
46. [46] Liakou, C.I., Kamat, A., Tang, D.N., Chen, H., Sun, J., Troncoso, P., et al. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A 105 (2008), 14987–14992, 10.1073/pnas.0806075105 [PubMed PMID: 18818309; PMCID: PMC2567480].
47. [47] Sharma, P., Allison, J.P., The future of immune checkpoint therapy. Science 348 (2015), 56–61, 10.1126/science.aaa8172 [PubMed PMID: 25838373].
48. [48] Harvey, C., Elpek, K., Duong, E., Simpson, T., Shu, C.J., Shallberg, L., et al. Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics. J Immunother Cancer, 3(Suppl 2), 2015, O9, 10.1186/2051-1426-3-S2-O9 [PubMed PMID: PMC4645516].
49. [49] Galsky, M.D., Hahn, N.M., Albany, C., Fleming, M.T., Starodub, A., Twardowski, P., et al. Phase II trial of gemcitabine+cisplatin+ipilimumab in patients with metastatic urothelial cancer. ASCO Meet Abstr, 34(Suppl 2), 2016, 357.
50. [50] Hamid, O., Robert, C., Daud, A., Hodi, F.S., Hwu, W.J., Kefford, R., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 369 (2013), 134–144, 10.1056/NEJMoa1305133 [PubMed PMID: 23724846; PMCID: PMC4126516].
51. [51] Brahmer, J., Reckamp, K.L., Baas, P., Crinò, L., Eberhardt, W.E., Poddubskaya, E., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373 (2015), 123–135, 10.1056/NEJMoa1504627 [PubMed PMID: 26028407].
52. [52] Motzer, R.J., Escudier, B., McDermott, D.F., George, S., Hammers, H.J., Srinivas, S., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373 (2015), 1803–1813, 10.1056/NEJMoa1510665 [PubMed PMID: 26406148].
53. [53] Plimack, E.R., Bellmunt, J., Gupta, S., Berger, R., Montgomery, R.B., Heath, K., et al. Pembrolizumab (MK-3475) for advanced urothelial cancer: updated results and biomarker analysis from KEYNOTE-012. ASCO Meet Abstr, 33(Suppl 15), 2015, 4502.
54. [54] Rosenberg, J.E., Hoffman-Censits, J., Powles, T., van der Heijden, M.S., Balar, A.V., Necchi, A., et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet, 2016, 10.1016/S0140-6736(16)00561-4 [PubMed PMID: 26952546].
55. [55] Nguyen, L.T., Ohashi, P.S., Clinical blockade of PD1 and LAG3—potential mechanisms of action. Nat Rev Immunol 15 (2015), 45–56, 10.1038/nri3790 [PubMed PMID: 25534622].
56. [56] Anderson, A.C., Tim-3: an emerging target in the cancer immunotherapy landscape. Cancer Immunol Res 2 (2014), 393–398, 10.1158/2326-6066.CIR-14-0039 [PubMed PMID: 24795351].
57. [57] Fourcade, J., Sun, Z., Pagliano, O., Guillaume, P., Luescher, I.F., Sander, C., et al. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res 72 (2012), 887–896, 10.1158/0008-5472.CAN-11-2637 [PubMed PMID: 22205715; PMCID: PMC3288235].
58. [58] Lines, J.L., Sempere, L.F., Broughton, T., Wang, L., Noelle, R., VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy. Cancer Immunol Res 2 (2014), 510–517, 10.1158/2326-6066.CIR-14-0072 [PubMed PMID: 24894088; PMCID: PMC4085258].
59. [59] Sanmamed, M.F., Pastor, F., Rodriguez, A., Perez-Gracia, J.L., Rodriguez-Ruiz, M.E., Jure-Kunkel, M., et al. Agonists of co-stimulation in cancer immunotherapy directed against CD137, OX40, GITR, CD27, CD28, and ICOS. Semin Oncol 42 (2015), 640–655, 10.1053/j.seminoncol.2015.05.014 [PubMed PMID: 26320067].
60. [60] Coe, D., Begom, S., Addey, C., White, M., Dyson, J., Chai, J.G., Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy. Cancer Immunol Immunother 59 (2010), 1367–1377, 10.1007/s00262-010-0866-5 [PubMed PMID: 20480365].
61. [61] Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9 (2003), 1269–1274, 10.1038/nm934 [PubMed PMID: 14502282].
62. [62] Zhai, L., Spranger, S., Binder, D.C., Gritsina, G., Lauing, K.L., Giles, F.J., et al. Molecular pathways: targeting IDO1 and other tryptophan dioxygenases for cancer immunotherapy. Clin Cancer Res 21 (2015), 5427–5433, 10.1158/1078-0432.CCR-15-0420 [PubMed PMID: 26519060; PMCID: PMC4681601].
63. [63] Gangadhar, T.C., Hamid, O., Smith, D.C., Bauer, T.M., Wasser, J.S., Luke, J.J., et al. Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers. J Immunother Cancer, 3(Suppl 2), 2015, O7, 10.1186/2051-1426-3-S2-O7 [PubMed PMID: PMC4645566].
64. [64] Spranger, S., Spaapen, R.M., Zha, Y., Williams, J., Meng, Y., Ha, T.T., et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med, 5, 2013, 200ra116, 10.1126/scitranslmed.3006504 [PubMed PMID: 23986400; PMCID: PMC4136707].
65. [65] Gajewski, T.F., Schreiber, H., Fu, Y.X., Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14 (2013), 1014–1022, 10.1038/ni.2703 [PubMed PMID: 24048123; PMCID: PMC4118725].
66. [66] Gajewski, T.F., Louahed, J., Brichard, V.G., Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J 16 (2010), 399–403, 10.1097/PPO.0b013e3181eacbd8 [PubMed PMID: 20693853].
67. [67] Tumeh, P.C., Harview, C.L., Yearley, J.H., Shintaku, I.P., Taylor, E.J., Robert, L., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515 (2014), 568–571, 10.1038/nature13954 [PubMed PMID: 25428505; PMCID: PMC4246418].
68. [68] Spranger, S., Bao, R., Gajewski, T.F., Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 523 (2015), 231–235, 10.1038/nature14404 [PubMed PMID: 25970248].
69. [69] Peng, W., Chen, J.Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M.T., et al. Loss of PTEN promotes resistance to T Cell-mediated immunotherapy. Cancer Discov 6 (2016), 202–216, 10.1158/2159-8290.CD-15-0283 [PubMed PMID: 26645196; PMCID: PMC4744499].
70. [70] Woo, S.R., Fuertes, M.B., Corrales, L., Spranger, S., Furdyna, M.J., Leung, M.Y., et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41 (2014), 830–842, 10.1016/j.immuni.2014.10.017 [PubMed PMID: 25517615; PMCID: PMC4384884].
71. [71] Corrales, L., Gajewski, T.F., Molecular pathways: targeting the stimulator of interferon genes (STING) in the immunotherapy of cancer. Clin Cancer Res 21 (2015), 4774–4779, 10.1158/1078-0432.CCR-15-1362 [PubMed PMID: 26373573; PMCID: PMC4750108].
72. [72] Woo, S.R., Corrales, L., Gajewski, T.F., The STING pathway and the T cell-inflamed tumor microenvironment. Trends Immunol 36 (2015), 250–256, 10.1016/j.it.2015.02.003 [PubMed PMID: 25758021; PMCID: PMC4393801].
73. [73] Sivan, A., Corrales, L., Hubert, N., Williams, J.B., Aquino-Michaels, K., Earley, Z.M., et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350 (2015), 1084–1089, 10.1126/science.aac4255 [PubMed PMID: 26541606].
74. [74] Gajewski, T.F., The next hurdle in cancer immunotherapy: overcoming the non-T-cell-inflamed tumor microenvironment. Semin Oncol 42 (2015), 663–671, 10.1053/j.seminoncol.2015.05.011 [PubMed PMID: 26320069; PMCID: PMC4555998].
75. [75] Massard, C., Gordon, M.S., Sharma, S., Rafii, S., Wainberg, Z.A., Luke, J., et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol, 2016, 10.1200/JCO.2016.67.9761 [PubMed PMID: 27269937].
76. [76] Ribas, A., Robert, C., Hodi, F.S., Wolchok, J.D., Joshua, A.M., Hwu, W.-J., et al. Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. ASCO Meet Abstr, 33(Suppl 15), 2015, 3001.
77. [77] Seiwert, T.Y., Burtness, B., Weiss, J., Eder, J.P., Yearley, J., Murphy, E., et al. Inflamed-phenotype gene expression signatures to predict benefit from the anti-PD-1 antibody pembrolizumab in PD-L1+head and neck cancer patients. ASCO Meet Abstr, 33(Suppl 15), 2015, 6017.
78. [78] Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J.M., Desrichard, A., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371 (2014), 2189–2399, 10.1056/NEJMoa1406498 [PubMed PMID: 25409260; PMCID: PMC4315319].
79. [79] Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128, 10.1126/science.aaa1348 [PubMed PMID: 25765070].
80. [80] Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., Kemberling, H., Eyring, A.D., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372 (2015), 2509–2520, 10.1056/NEJMoa1500596 [PubMed PMID: 26028255; PMCID: PMC4481136].
81. [81] Gubin, M.M., Zhang, X., Schuster, H., Caron, E., Ward, J.P., Noguchi, T., et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515 (2014), 577–581, 10.1038/nature13988 [PubMed PMID: 25428507; PMCID: PMC4279952].
82. [82] Yadav, M., Jhunjhunwala, S., Phung, Q.T., Lupardus, P., Tanguay, J., Bumbaca, S., et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515 (2014), 572–576, 10.1038/nature14001 [PubMed PMID: 25428506].
83. [83] Robins, H., Immunosequencing: applications of immune repertoire deep sequencing. Curr Opin Immunol 25 (2013), 646–652, 10.1016/j.coi.2013.09.017 [PubMed PMID: 24140071].
84. [84] Linnemann, C., Mezzadra, R., Schumacher, T.N., TCR repertoires of intratumoral T-cell subsets. Immunol Rev 257 (2014), 72–82, 10.1111/imr.12140 [PubMed PMID: 24329790].
85. [85] Kirsch, I., Vignali, M., Robins, H., T-cell receptor profiling in cancer. Mol Oncol 9 (2015), 2063–2070, 10.1016/j.molonc.2015.09.003 [PubMed PMID: 26404496].
86. [86] Choudhury, N.J., Kiyotani, K., Yap, K.L., et al. Low T-cell receptor diversity, high somatic mutation burden, and high neoantigen load as predictors of clinical outcome in muscle-invasive bladder cancer. Eur Urol Focus 2 (2016), 445–452, 10.1016/j.euf.2015.09.007.
87. [87] Choi, W., Porten, S., Kim, S., Willis, D., Plimack, E.R., Hoffman-Censits, J., et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25 (2014), 152–165, 10.1016/j.ccr.2014.01.009 [PubMed PMID: 24525232; PMCID: PMC4011497].
88. [88] Damrauer, J.S., Hoadley, K.A., Chism, D.D., Fan, C., Tiganelli, C.J., Wobker, S.E., et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A 111 (2014), 3110–3115, 10.1073/pnas.1318376111 [PubMed PMID: 24520177; PMCID: PMC3939870].
89. [89] Sharma, P., Allison, J.P., Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161 (2015), 205–214, 10.1016/j.cell.2015.03.030 [PubMed PMID: 25860605].